



Onyx Dkt No. 1046.ORD
USSN: 09/410,462
PATENT

CERTIFICATE OF FIRST CLASS MAILING (37 CFR 1.8)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the following date:

17 Jan 2006
Date

Gary R. Fabre
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	
In Re Application of: Williams, A., et al.	Confirmation No. 6889
Serial No.: 09/410,462	Art Unit: 1635
Filing Date: 1 October 1999	Examiner: J.E. Angell
Title: A SINGLE AGENT METHOD FOR KILLING TUMOR AND TUMOR ASSOCIATED ENDOTHELIAL CELLS USING ADENOVIRAL MUTANTS	

TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-referenced application are the following documents:

1. Transmittal;
2. A Request for Continued Prosecution, including authorization to charge Deposit Account the required fee of \$395.00 (small entity rate) (in duplicate);
3. A Request for a One-Month Extension of Time, including authorization to charge Deposit Account the required fee of \$60.00 (small entity rate) (in duplicate);
4. Amendment And Response Accompanying RCE, including complete listing of the claims, and amendments to the specification (**no additional fee for the newly presented claims is believed due as the present amendment adds six dependent**

claims and cancels eight claims (including six dependent claims and two independent claims));

5. Information Disclosure Statement, modified form 1449, and copies of one cited, non-U.S. Patent publications;
6. Statement Under 37 CFR §1.825;
7. CD-ROM comprising computer-readable form of the Sequence Listing;
8. A paper copy of the Sequence Listing;
9. Certificates of First Class Mailing; and
10. Return Receipt Postcard.

Authorization to Charge Deposit Account.

No additional fees are believed due. However, the Commissioner is hereby authorized to charge to Deposit Account No. 15-0615 any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

Dated: 17 Jan 2006

By : Gary R. Fabian
Gary R. Fabian, Ph.D.
Registration No. 33,875
Agent for Applicants

ONYX Pharmaceuticals, Inc.
2100 Powell Street
Emeryville, CA 94608
Phone: (510) 597-6502
Facsimile: (510) 597-6610